Message To Shareholders/Investors

In 2024, the Phase IIb study of H-1337, a glaucoma treatment that we have been focusing on for the past few years, produced positive results, leading to an increase in corporate value. In 2025, we hope to grow this business significantly.
In addition, we have started Phase II study of DWR-2206, the regenerative medicine cell product in Japan, and have completed the administration of the drug. We are looking forward to the results in 2025. We are focusing on the field of ophthalmology, and by working on not only small molecules (kinase inhibitors) but also other modalities, we hope to provide patients with treatment options for a variety of eye diseases.

For the past five years, we have set the medium-term management target themes of “expansion of our pipeline” and “expansion of our business fields,”. As a result, the number of projects in our pipeline has doubled, and we have set up a system that allows us to conduct clinical development in-house.
We will continue to invest in research and development in 2025. The source of the competitiveness of bio-ventures is their pipelines. We will continue to focus on research and development activities in order to enhance these pipelines. Although uncertainty in new drug development remains high, technological innovation is also progressing, and competition continues to intensify. Under such circumstances, we will actively collaborate with other companies with the aim of further demonstrating our technical capabilities in useful basic research and promote our business to deliver valuable new drugs to patients.
And we will also continue to work on our own clinical trials. The success of clinical trials is expected to lead to a dramatic increase in value, so we would like to create our next in-house product, advance it to clinical development, and open the door to a new stage.

The development of new drugs takes much more time and is more difficult than one might imagine, but because of the high social significance of this work, we always feel that we are supported by many people. The social situation is changing rapidly, and it is sometimes difficult to respond, but we are determined to sincerely meet the expectations of all our stakeholders, including our shareholders and investors.

We will continue to grow based on our founding philosophy of “bringing innovative new medicines from Japan to the world”. And we will continue to develop our business in order to create new corporate value that meets the expectations of our shareholders and investors.

We sincerely appreciate the continued supports of our shareholders and all stakeholders.

President and CEO Yuichi Hidaka